Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial...

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Glycoprotein IIb/IIIa inhibitors like abciximab are crucial in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI).
• Previous small studies suggested potential benefits of intracoronary abciximab over intravenous administration, but lacked robust clinical trial evidence.

Purpose of the Study:

• To evaluate the efficacy of intracoronary versus intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention.
• To compare key reperfusion markers and clinical outcomes between the two administration routes.

Main Methods:

• A medium-scale randomized clinical trial involving 534 STEMI patients undergoing primary percutaneous coronary intervention with thrombus aspiration.
• Patients received either intracoronary or intravenous abciximab (0.25 mg/kg) following pretreatment with aspirin, heparin, and clopidogrel.
• Primary endpoint: ST-segment resolution; Secondary endpoints: myocardial blush grade, enzymatic infarct size, and 30-day major adverse cardiac events.

Main Results:

• Complete ST-segment resolution rates were similar between intracoronary and intravenous abciximab groups (64% vs. 62%, P=0.562).
• Intracoronary administration resulted in a significantly higher incidence of myocardial blush grade 2/3 (76% vs. 67%, P=0.022) and smaller enzymatic infarct size (P=0.008).
• Major adverse cardiac events at 30 days were comparable between the groups (5.5% vs. 6.1%, P=0.786).

Conclusions:

• Intracoronary abciximab does not improve ST-segment resolution compared to intravenous administration in STEMI patients undergoing primary PCI with thrombus aspiration.
• However, intracoronary administration is associated with enhanced myocardial reperfusion (myocardial blush grade) and reduced enzymatic infarct size.